4/5
08:03 am
hoth
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
3/27
02:11 pm
hoth
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds [Yahoo! Finance]
3/27
02:00 pm
hoth
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
Medium
Report
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
3/27
08:32 am
hoth
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment [Yahoo! Finance]
High
Report
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment [Yahoo! Finance]
3/27
08:27 am
hoth
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
Medium
Report
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
3/20
07:23 am
hoth
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data [Yahoo! Finance]
Medium
Report
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data [Yahoo! Finance]
3/19
09:54 am
hoth
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ [Yahoo! Finance]
3/19
08:21 am
hoth
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Medium
Report
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
2/29
08:53 am
hoth
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio [Yahoo! Finance]
2/29
08:38 am
hoth
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
Medium
Report
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
2/26
08:31 am
hoth
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic [Yahoo! Finance]
Low
Report
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic [Yahoo! Finance]
2/26
08:11 am
hoth
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
Low
Report
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
2/13
11:45 am
hoth
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
Low
Report
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
2/5
08:03 am
hoth
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $4.00 price target on the stock.